Physicians' Academy for Cardiovascular Education

Diabetes & CVD

Diabetes type II confers an increased CVD risk. Recent scientific developments have yielded antidiabetic agents that positively impact CV risk in diabetic patients. Follow the latest insights into the close link between diabetes and CVD.

Translating GLP-1RA trial outcomes to cardiology practice: Which patients will benefit?

10' education - Dec. 10, 2018 - Prof. Lars Rydén, MD - Stockholm Sweden

Current and future clinical approaches to manage HFpEF

10' education - Aug. 27, 2018 - Burkert Pieske, MD - Berlin, Germany

GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Filip K. Knop - Copenhagen, Denmark

SGLT2 inhibitor treatment may now be considered in broader T2DM population

3' education - Nov. 11, 2018 - Steve Wiviott, MD - Boston, MA, VS.

HFpEF: What are the most likely pathophysiological mechanisms involved in the disease

10' education - Aug. 27, 2018 - Carolyn Lam, MD - Singapore

Diabetes & CVD: Time for a multifactorial approach

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany

Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Villingen-Schwenningen, Germany

The real residual risk in patients with CVD & diabetes: The promise of epigenetics

10' education - Aug. 25, 2018 - ESC 2018 - Munich, Germany - Prof. Erik Stroes, MD - Amsterdam, The Netherlands

In a primary prevention setting of diabetes patients, aspirin did not give overall benefit

3' education - Aug. 27, 2018 - Prof. Jane Armitage, Oxford, UK

Weight loss agent showed CV safety in high-risk patients with overweight or obesity

3' education - Aug. 26, 2018 - Dr. Erin Bohula, Boston, MA, US

No CV benefit with omega-3 fatty acid supplements

3' education - Aug. 26, 2018

HFpEF: from understanding the physiology to development of new treatments

10' education - May 27, 2018 - ESC Heart Failure 2018, Vienna - Carolyn Lam, MD - Singapore - Online CME

Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks

10' education - Mar. 29, 2018 - Prof Cliff Bailey - Birmingham, UK

Understanding the mechanisms of SGLT2 inhibition in heart failure and diabetes

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Naveed Sattar - Glasgow, UK

Current management of heart failure and T2DM

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Martin Cowie - London, UK

Guidance from outcome trials: What are the clinical implications?

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Faiez Zannad - Nancy, France

Understanding CKD and SGLT2-inhibition: What are the key mechanisms?

10' education - May 25, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Per-Henrik Groop - Helsinki, Finland

Remaining questions on SGLT2 inhibition & CKD: A review of new outcome trials

10' education - July 12, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Colin Baigent - Oxford, United Kingdom

SGLT2 inhibition in kidney disease: key lessons from EMPA-REG OUTCOME

10' education - July 11, 2018 - ERA-EDTA - Copenhagen, Denmark - Prof. Christoph Wanner - Würzburg, Germany - Online CME

Greater absolute benefit with PCSK9 inhibition in diabetes patients

3' education - July 3, 2018 - Prof. Kausik Ray, Imperial College London, UK
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - June 25, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

Familial dysbetalipoproteinemia: Pathofysiology, diagnosis and treatment

10' education - Apr. 11, 2018 - Charlotte Koopal - Utrecht, The Netherlands

Novel diabetes drugs in clinical management: Extending the opportunities

10' education - June 5, 2018 - Stefano Taddei, Cees Tack, Massimo Volpe

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya

What are the key mechanisms of CV benefit of novel diabetes drugs?

10' education - May 1, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar

What is the science driving CVD and T2DM?

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser

Physical activity should be stressed more in T2DM, as it reduces mortality

News - Jan. 15, 2019

EAPC Position Statement states that exercise programs for diabetics are a cost effective treatment and should be reimbursed.

Relative risk of CV events similarly increased with resting heart rate irrespective of diabetes status

Literature - Jan. 14, 2019 - Böhm M et al., - Eur Heart J 2018

In patients at high CV risk, higher absolute event rates were seen across the RHR spectrum in those with diabetes, but the relative risk increase based on RHR was similar for those with and without diabetes.

SGLT2 inhibitor may give clinically relevant BP reductions in T2DM with nocturnal hypertension

Literature - Jan. 8, 2019 - Kario K et al., - Circulation. 2018

In the SACRA study, treatment with empagliflozin for 12 weeks was associated with reductions from baseline in nighttime, clinic, 24-hour ABP and morning HBP in T2DM with uncontrolled nocturnal hypertension.

Summary | Changing focus in diabetes: From glucose to CV risk management

Munich, Berlin - August 27, 2018

This is a summary of the presentation by prof. Stephan Jacob, in which he talked about the management of diabetes, focusing on the shift from glucose to CV risk management in patients with diabetes.

Summary | SGLT2 inhibition in cardiology: What is the profile of benefit?

Munich, Berlin - August 27, 2018

This is a summary of the presentation by prof. Nikolaus Marx, in which he addressed the mode of action of SGLT2 inhibitors, and presented clinical outcome data and potential mechanisms.

Diabetic Kidney Disease: Exploring mechanisms and outcomes of SGLT2 inhibition

CME accredited E-Learning

Online-CME - Online-CME - This course consists of 3 separate lectures
Online-CME - This course consists of 3 separate lectures

CME accredited course focussed on the role of SGLT2 inhibitors in the management of patients with Diabetic Kidney Disease. Member registration (free) is needed to enroll in this course

Treatment benefit of GLP-1RA in elderly with T2DM may vary with age

Literature - Dec. 18, 2018 - Gilbert MP et al., - Ann Intern Med. 2018
A posthoc analysis of the LEADER trial showed that liraglutide showed more pronounced CV benefits in T2DM patients aged 75 years or older, than in those between 60 and 74 years of age.

A posthoc analysis of the LEADER trial showed that liraglutide showed more pronounced CV benefits in T2DM patients aged 75 years or older, than in those between 60 and 74 years of age.

Exploring the role of GLP-1 RA in the management of CVD & T2DM

CME accredited E-Learning

Online-CME - Online-CME - This course consists of 5 panel discussions
Online-CME - This course consists of 5 panel discussions

CME accredited course focussed on how new developments with antidiabetic drugs will impact the management of CVD. Member registration (free) is needed to enroll in this course

PCSK9-targeted siRNA therapy: effective, safe and durable lipid-lowering irrespective of diabetes status

Literature - Dec. 11, 2018 - Leiter LA et al. - Diabetes Care 2018
A post-hoc analysis showed reduced LDL-c levels and improved lipid profiles up to 180 days with one or two doses of inclisiran on top of standard care in the presence and absence of diabetes, compared to placebo.

A post-hoc analysis showed reduced LDL-c levels and improved lipid profiles up to 180 days with one or two doses of inclisiran on top of standard care in the presence and absence of diabetes, compared to placebo.

Type of existing CVD at baseline affects CV benefits of SGLT2 inhibition

Literature - Dec. 10, 2018 - Zelniker TA et al. - The Lancet 2018
A meta-analysis of three CVOTs showed moderate benefits of SGLT2i on atherosclerotic MACE only in those with ASCVD, whereas robust benefits on HHF and renal disease were observed regardless of baseline CVD or HF.

A meta-analysis of three CVOTs showed moderate benefits of SGLT2i on atherosclerotic MACE only in those with ASCVD, whereas robust benefits on HHF and renal disease were observed regardless of baseline CVD or HF.

Translating GLP-1RA trial outcomes to cardiology practice: Which patients will benefit?

10' education - Dec. 10, 2018 - Prof. Lars Rydén, MD - Stockholm Sweden
Different GLP-1RAs have shown different effects in CV outcomes trials. Prof Rydén scrutinizes the results of the trials to learn more about the effects of individual GLP-1RAs and what the differences may originate from.

Different GLP-1RAs have shown different effects in CV outcomes trials. Prof Rydén scrutinizes the results of the trials to learn more about the effects of individual GLP-1RAs and what the differences may originate from.

ACC Expert Consensus Decision Pathway gives recommendations on use of novel anti-diabetes drugs

News - Dec. 4, 2018

Expert Consensus Decision Pathways are meant to complement guidelines and bridge remaining gaps in clinical guidance, in this case the use of SGLT2 inhibitors and GLP-1RAs to lower CV risk in T2DM.